معرفی
Andrew Martin is a Professorial Research Fellow at the University of Queensland's School of Health and Rehabilitation Sciences, where he leads the UQ’s cLinical Trials cApability (ULTRA) program. He holds an honorary position at the NHMRC Clinical Trials Centre, University of Sydney, following senior roles in pharmaceutical biostatistics at Pfizer and Roche. His research focuses on innovative clinical trial methodologies, biostatistics, and oncology, particularly prostate cancer, gastrointestinal cancers, and neonatal interventions.
Research interests span:
- Clinical Trial Design: Developing accelerated protocols for cancer and neonatal studies.
- Cancer Therapeutics: PSMA-targeted radioligand therapy (e.g., TheraP, ENZAMET trials), regorafenib in gastric cancer (INTEGRATE trials), and biomarker-driven treatment strategies.
- Precision Medicine: Utilizing lipidomics, ctDNA, and genomic biomarkers (e.g., HSD3B1) for personalized oncology.
- Neonatal Health: Optimizing outcomes for very-low-birthweight infants (e.g., LIFT trial on lactoferrin supplementation).
Martin has secured extensive grant funding, including:
- NHMRC grants: $14.3M (Category 1) and $131.8M (Category 3).
- Key projects: P3BEP Trial ($1.36M), PROMs healthcare systems ($1.17M), ENZAMET prostate cancer study, and industry-funded trials (ENZARAD, INTEGRATE series totaling >$120M).
He directs the ULTRA program, enhancing clinical trial infrastructure, and collaborates internationally through ANZUP Cancer Trials Group. Education and studentships are not detailed. No scientific awards are mentioned.
